PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig

View source ↗

Summary

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommends additional measures to reduce the risk of blood vessel blockage with Iclusig (ponatinib)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia in Blast Crisis
• Philadelphia Chromosome-positive Leukemias

Drugs mentioned

• Iclusig (ponatinib)